Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports-March 2024-www.financetom.com

Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports

Oct 10, 2025 8:43 AM

Oct 10 (Reuters) - Johnson & Johnson ( JNJ ) is in

discussions to buy Protagonist Therapeutics ( PTGX ), the Wall

Street Journal reported on Friday, citing people familiar with

the matter.

Shares of Protagonist were up 9.4% in morning trade.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Anil

D'Silva)

Previous page： Alcoa Swings to Profit in Q4, Revenue Increases Next page： B2Gold Down 8.3% After Hours as it Seeks US$350 Million in an Offering of Convertible Senior Notes

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Alcoa Swings to Profit in Q4, Revenue Increases

Jan 22, 2025

04:33 PM EST, 01/22/2025 (MT Newswires) -- Alcoa ( AA ) reported Q4 adjusted earnings Wednesday of $1.04 per diluted share, compared with a per-share loss of $0.56 a year earlier. Analysts polled by FactSet expected earnings of $0.95 per share. Revenue for the quarter ended Dec. 31 was $3.49 billion, up from $2.60 billion a year earlier. Analysts surveyed...

B2Gold Down 8.3% After Hours as it Seeks US$350 Million in an Offering of Convertible Senior Notes

Jan 22, 2025

04:29 PM EST, 01/22/2025 (MT Newswires) -- B2Gold ( BTG ) was last seen down 8.3% in after-hours New York trading after the company after trade Wednesday said it is raising US$350 million in an offering of convertible senior unsecured notes due 2030. The company said the interest rate on the securities and the conversion price will be set at...

Gitlab Insider Sold Shares Worth $601,315, According to a Recent SEC Filing

Jan 22, 2025

04:35 PM EST, 01/22/2025 (MT Newswires) -- Robin Schulman, Chief Legal Officer & Corporae Secretary, on January 17, 2025, sold 9,251 shares in Gitlab ( GTLB ) for $601,315. Following the Form 4 filing with the SEC, Schulman has control over a total of 121,893 shares of the company, with 121,893 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1653482/000162828025002195/xslF345X05/wk-form4_1737581321.xml ...

CACI International Fiscal Q2 Adjusted Earnings, Revenue Increase; Fiscal 2025 Outlook Updated

Jan 22, 2025

04:26 PM EST, 01/22/2025 (MT Newswires) -- CACI International ( CACI ) reported fiscal Q2 adjusted earnings late Wednesday of $5.95 per diluted share, up from $4.36 a year earlier. Analysts polled by FactSet expected $5.20. Revenue for the quarter ended Dec. 31 rose to $2.10 billion from $1.83 billion a year earlier. Analysts surveyed by FactSet expected $2.04 billion....